Basic Provera Information

• INN (International Nonproprietary Name): Medroxyprogesterone Acetate
• Brand Names Available In Australia: not specified
• ATC Code: G03DA02
• Forms & Dosages: Oral tablets 2.5 mg, 5 mg, 10 mg (bottles of 30, 100, 500); Injectable forms 104 mg (Depo-SubQ) and 150 mg (Depo-Provera) in vials or prefilled syringes.
• Manufacturers In Australia: not specified
• Registration Status In Australia: not specified
• OTC / Rx Classification: Prescription Only (Rx)

Key Findings From Recent Trials

Worried about safety signals and whether injectable contraception still stacks up?

Recent literature from 2022 to 2025 has reinforced two clear themes about medroxyprogesterone acetate: good contraceptive efficacy with adherence for injectables and ongoing bone mineral density and fertility return concerns for long‑term injectable users.

Australian cohort studies and global registries have focused on adolescents and women using depot injections and tracked long‑term BMD trajectories and bleeding outcomes.

Randomised trials and pragmatic observational studies show oral tablet regimens of 5–10 mg daily for 5–10 days reliably induce withdrawal bleeding in abnormal uterine bleeding and are commonly used in HRT cycles.

Injectable dosage real data include Depo‑Provera 150 mg IM and Depo‑SubQ Provera 104 mg SQ given every three months for contraception.

TGA pharmacovigilance reports mirror international signals reporting injection‑site reactions, menstrual irregularities, weight change and rare thromboembolic events.

Safety guidance supports targeted counselling on BMD, mood effects and limiting continuous injectable use without bone health review.

Practical counselling now emphasises duration review, calcium and vitamin D measures and consideration of alternatives where BMD risk is present.

Main Outcomes

Injectable medroxyprogesterone acetate maintains high contraceptive effectiveness when dosing schedules are followed.

Tablet Provera reliably induces withdrawal bleeding and provides endometrial protection when prescribed as 5–10 mg courses.

Adherence advantages are clear for the three‑monthly injectable over daily oral dosing in routine Australian practice.

Safety Observations (TGA Reports)

TGA summaries align with international data noting injection‑site reactions and menstrual irregularities as common events.

Weight change and mood disturbances are recorded as frequent adverse effects in post‑market surveillance.

Rare thromboembolic events are described and underline standard contraindication screening for vascular risk.

Clinical Mechanism Of Action

Want a simple explanation of what Provera does in your body?

Provera, the tablet form of medroxyprogesterone acetate, is a synthetic progestogen that mimics natural progesterone to regulate the menstrual cycle and stop abnormal bleeding.

In injectable form as Depo‑Provera or Depo‑SubQ it provides prolonged systemic progestin levels that reliably prevent ovulation for contraception.

At the receptor level medroxyprogesterone acetate binds progesterone receptors in the hypothalamus, pituitary and endometrium.

That receptor binding reduces gonadotropin release which suppresses ovulation and causes endometrial thinning and decidualisation.

These endometrial effects are why tablets are effective for inducing withdrawal bleeding and protecting the endometrium during oestrogen replacement.

Systemic impacts include central nervous system modulation that can affect mood, measurable shifts in lipid metabolism and potential effects on bone remodelling with sustained exposure from injectables.

Injectable dosing provides prolonged receptor occupancy while oral cyclical dosing acts as luteal‑phase progesterone replacement in HRT regimens.

Because medroxyprogesterone acetate is metabolised hepatically exercise caution in significant liver impairment where use is contraindicated.

Receptor-Level Effects

Progesterone receptor agonism suppresses LH/FSH secretion and prevents follicular maturation and ovulation when levels are sustained.

Systemic Impacts (Endometrium, CNS)

Endometrial thinning reduces bleeding and lowers the risk of hyperplasia when used with oestrogen replacement.

CNS effects can include mood changes, headaches and somnolence reported in surveillance data.

Scope Of Approved And Off‑Label Use

Curious which uses are TGA‑approved and which are common off‑label in Australia?

TGA approvals cover medroxyprogesterone acetate for menstrual disorders, endometrial protection in HRT and as a contraceptive injection.

Formulations include tablets (2.5, 5 and 10 mg) and injectables (104 mg and 150 mg) supplied under brand names globally.

PBS listing varies by formulation and indication and is not universally applied to every Provera product.

In practice many oral Provera tablets are supplied via private prescription unless they are part of a subsidised HRT item on the PBS.

Notable off‑label trends in Australia include short‑course induction of menses with oral Provera, use as a medical bridge for heavy menstrual bleeding when LNG‑IUS is unsuitable and HRT sequential regimens.

Injectable medroxyprogesterone is sometimes chosen in remote and residential aged‑care settings to reduce clinic visit frequency despite bone health monitoring needs.

Family planning services balance contraception benefits with BMD risks when counselling about Depo‑Provera.

Dosage Strategy

Need clear dosing so the pharmacist and patient are on the same page?

General oral dosing for abnormal uterine bleeding or secondary amenorrhoea is 5–10 mg daily for 5–10 days, typically starting on day 16–21 of the cycle.

For endometrial protection during oestrogen therapy the standard is 5–10 mg daily for 12–14 consecutive days each month.

Contraceptive injections follow the real data schedules: Depo‑Provera 150 mg IM every 12 weeks or Depo‑SubQ 104 mg SQ every 12 weeks.

Clinical recommendations advise reviewing continued injectable use beyond two years because of bone density concerns.

Missed oral dose guidance is to take a missed tablet the same day if remembered, but do not double up if it is near the next dose.

For a missed injection administer as soon as possible and use backup contraception according to fertility planning.

Practically include calendar reminders for injections and document counselling at dispensing for oral courses addressing withdrawal bleeding timing and expectations.

Safety Protocols

Worried about whether Provera is safe for you or someone you care for?

Absolute contraindications follow TGA‑aligned guidance and include known hypersensitivity, active or prior thromboembolic disease, suspected or diagnosed breast or genital malignancy, undiagnosed vaginal bleeding, significant liver disease and pregnancy until excluded.

Relative contraindications that require monitoring include history of depression, migraine, epilepsy, and significant cardiovascular or osteoporosis risk.

Post‑market pharmacovigilance lists common adverse effects as menstrual irregularities, weight gain, headache, breast tenderness and mood changes.

Injectable‑specific reports cite injection‑site reactions, delayed return to fertility and BMD decline with prolonged use.

TGA adverse event summaries reflect these known patterns and recommend baseline risk assessment and periodic review for long‑term injectable users.

When dispensing, ensure contraindication screening is documented and consider referral if risk factors for thromboembolism or bone loss are present.

Interaction Mapping

Worried about whether your other medicines or lifestyle choices will interfere with Provera?

There are no major food interactions requiring avoidance of coffee or particular foods for medroxyprogesterone acetate tablets.

Alcohol can exacerbate dizziness or mood side effects and counselling on moderation is recommended, especially in rural patients where alcohol use may be higher.

Drugs that induce hepatic enzymes such as certain anticonvulsants, rifampicin and St John’s Wort can reduce progestin plasma levels and potentially reduce contraceptive effectiveness.

Concurrent use of systemic corticosteroids, anticoagulants and some psychotropic medicines requires monitoring for additive effects.

Avoid combined oestrogen products in patients with high thromboembolic risk and consider alternative contraception where interactions could impair reliability.

Pharmacists should check all prescribed and OTC medicines at dispensing and record counselling, especially when e‑scripts arrive from telehealth providers.

Patient Experience Analysis

What do Australian women say about using Provera and depot injections?

Survey data in Australia show injectable users prioritise contraceptive reliability and fewer clinic visits while oral Provera users favour rapid control of bleeding.

Rural respondents value injectables for access reasons and urban patients more often choose LNG‑IUS or oral alternatives when available.

Commonly reported adverse experiences include irregular bleeding, weight change and mood variability.

Online forums and e‑pharmacy search trends show price sensitivity and frequent searches like "buy Provera online" and "Depo‑Provera for contraception".

Pharmacists in chains report frequent counselling questions on fertility return after Depo‑Provera and on managing breakthrough bleeding with oral tablets.

Telehealth scripts have increased remote access but can make continuity of monitoring—such as bone health checks and mood follow‑up—more challenging.

Distribution And Pricing Landscape

How easy is it to get Provera in Australia and what will it cost?

Provera tablets and Depo‑Provera injectables are widely stocked in Australian pharmacies and family planning clinics, with generics available through major chains.

Major national pharmacy chains such as Chemist Warehouse, Priceline and TerryWhite commonly supply generic tablets while injectables are often provided through clinic partnerships or wholesalers.

Pfizer is identified as a primary global supplier for branded Provera tablets and multiple generics exist for oral forms.

PBS subsidy varies by formulation and indication so some HRT items are subsidised while many oral tablets require a private script unless part of a funded program.

Contraceptive injections may be available at low cost or free through public family planning services and state programs, while private prescriptions incur out‑of‑pocket cost.

Online pharmacy growth and telehealth e‑scripts have increased private purchase pathways and discreet delivery options to Australia in 5–14 days for customers using private channels.

Rural logistics can affect cold‑chain maintenance and timely supply for injectables, so planning ahead is important for remote patients.

Alternative Options

Looking for options other than Provera for bleeding control, contraception or HRT protection?

Alternatives include norethisterone acetate, micronised progesterone, drospirenone, levonorgestrel products (including LNG‑IUS) and dydrogesterone depending on the indication.

Each alternative has different pros and cons for bleeding control, contraception efficacy and side‑effect profile.

Depo‑Provera offers high adherence and infrequent dosing but carries BMD concerns and a possible delay in fertility return after stopping.

Oral Provera is convenient for short‑course induction of menses but requires patient adherence across the course and can cause irregular bleeding.

LNG‑IUS provides excellent bleeding control and long‑acting contraception but needs a procedure for insertion and may have upfront costs.

Micronised progesterone may be preferred by some for mood tolerability but is not a contraceptive in the same way as depot injections.

Check PBS listing and patient concession eligibility to compare subsidised vs private cost options before prescribing or dispensing.

Regulatory Status

How is medroxyprogesterone acetate regulated and subsidised in Australia?

Medroxyprogesterone acetate is a prescription‑only medication in reviewed markets and TGA‑aligned SPCs provide approval for menstrual disorders, HRT endometrial protection and contraceptive injection use.

TGA pharmacovigilance monitors adverse events such as BMD changes, thromboembolism and mood effects and issues safety communications when required.

PBS subsidy requires submission of clinical and pharmacoeconomic evidence and whether a specific Provera formulation is subsidised depends on the PBS decision for each indication.

Contraceptive injections are often funded through public health clinics or family planning services rather than listed directly on the PBS for general outpatient supply.

Pharmacists and prescribers should check the PBS schedule and any authority requirements before dispensing to confirm subsidy eligibility.

Storage and labelling requirements apply and injectables must be stored within recommended temperature ranges during pharmacy handling and transport.

Consolidated FAQ

Will Depo‑Provera Affect My Future Fertility?

Fertility usually returns after the last injection but return to conception can be delayed by several months, so discuss family planning timelines with a clinician.

Is Provera Covered By PBS?

Coverage depends on the formulation and indication; some HRT items are PBS‑subsidised while contraception injections may be provided through public clinics or state programs.

How Does Provera Affect Bone Health?

Long‑term use of injectable medroxyprogesterone is associated with reductions in bone mineral density and duration beyond two years should trigger a risk‑benefit review.

Can I Take Provera With Other Medicines?

Enzyme inducers such as some anticonvulsants, rifampicin and St John’s Wort can reduce effectiveness, so disclose all medicines and OTC products to the pharmacist.

Where Can I Get Counselling In Rural Australia?

Community pharmacies including TerryWhite, public family planning clinics and telehealth providers can provide counselling and injection services with planning for follow‑up monitoring.

Visual Guide

Which visuals help patients and pharmacists quickly understand forms, costs and counselling points?

Infographic 1 should show "Forms & Dosages At A Glance" listing medroxyprogesterone acetate INN, tablet strengths 2.5/5/10 mg and injectable strengths 104/150 mg with packaging examples.

Infographic 2 should map "PBS Vs Private Pathway" from prescription to PBS eligibility check, public clinic provision and private pharmacy/telehealth options.

Infographic 3 should present "Key Counselling Points" for pharmacists covering contraindications, missed dose rules, BMD review triggers and side‑effect management.

A distribution map can highlight national chains like Chemist Warehouse, Priceline and TerryWhite as urban supply hubs and show remote clinic pathways and cold‑chain nodes.

Design notes: use plain language, icons for bone and calendar and include TGA/PBS disclaimers where relevant.

Storage And Transport

How should patients and pharmacies store Provera in hot Australian conditions?

Store oral tablets at or below 25–30°C, away from direct sunlight and moisture and keep them out of reach of children.

Injectables require storage at 15–30°C, protected from light and must not be frozen.

Community pharmacies should monitor ambient storage temperatures and document batch handling for online orders and clinic supplies.

Cold‑chain logistics for injectables require validated temperature‑controlled storage and transport for remote deliveries, particularly for Depo‑SubQ prefilled syringes.

Plan contingencies for heatwaves and shipping delays to maintain product integrity in rural Australia.

Dispose of unused or expired tablets at pharmacy take‑back and return sharps to local health services in approved containers.

Guidelines For Proper Use

What should pharmacists say when dispensing Provera to ensure safe, informed use?

Adopt an evidence‑based, empathetic counselling style assessing indication, pregnancy status, smoking and cardiovascular risk and mental health history.

Provide clear oral dosing instructions including course length and missed dose rules and explain injection scheduling and backup contraception if an injection is late.

Discuss side effects such as irregular bleeding, mood changes and weight change and document counselling especially where follow‑up may be limited.

Follow TGA‑aligned SPCs and PBS rules and review injectable duration beyond two years with bone health considerations and offer alternatives like LNG‑IUS or oral progestins.

Use local family planning services for referral and ensure prescriptions meet regulatory labelling and storage requirements before dispensing.

Delivery Across Australia